Cargando…

Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction

Recent large placebo-controlled trials of sodium glucose co-transporter 2 (SGLT2) inhibitors revealed desirable effects on heart failure (HF) and renal dysfunction; however, the mechanisms underlying these effects are unknown. The characteristic changes in the early stage of diabetic cardiomyopathy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wakisaka, Masanori, Kamouchi, Masahiro, Kitazono, Takanari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888253/ https://www.ncbi.nlm.nih.gov/pubmed/31726765 http://dx.doi.org/10.3390/ijms20225668

Ejemplares similares

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects
por: Takashima, Masamitsu, et al.
Publicado: (2022)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study
por: Matsuo, Ryu, et al.
Publicado: (2016)

Non-linear association between body weight and functional outcome after acute ischemic stroke
por: Wakisaka, Kayo, et al.
Publicado: (2023)

Association of Embolic Sources With Cause-Specific Functional Outcomes Among Adults With Cryptogenic Stroke
por: Kiyuna, Fumi, et al.
Publicado: (2018)

Causes of ischemic stroke in young adults versus non-young adults: A multicenter hospital-based observational study
por: Ohya, Yuichiro, et al.
Publicado: (2022)

Association between decreases in serum uric acid levels and unfavorable outcomes after ischemic stroke: A multicenter hospital-based observational study
por: Nakamura, Kuniyuki, et al.
Publicado: (2023)

Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study
por: Atarashi, Hirotsugu, et al.
Publicado: (2021)

Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor
por: Yoshizumi, Hideyuki, et al.
Publicado: (2018)

Predictive role of C reactive protein in stroke recurrence after cardioembolic stroke: the Fukuoka Stroke Registry
por: Kuwashiro, Takahiro, et al.
Publicado: (2013)

Magnetic Resonance Imaging in Breath-Hold Divers with Cerebral Decompression Sickness
por: Matsuo, Ryu, et al.
Publicado: (2014)

Regional Disparity of Reperfusion Therapy for Acute Ischemic Stroke in Japan: A Retrospective Analysis of Nationwide Claims Data from 2010 to 2015
por: Maeda, Megumi, et al.
Publicado: (2021)

Nationwide temporal trend analysis of reperfusion therapy utilization and mortality in acute ischemic stroke patients in Japan
por: Maeda, Megumi, et al.
Publicado: (2021)

Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells
por: Wakisaka, Masanori, et al.
Publicado: (2016)

A CADASIL-Like Case with a Novel Noncysteine Mutation of the NOTCH3 Gene and Granular Deposits in the Renal Arterioles
por: Nakamura, Kuniyuki, et al.
Publicado: (2015)

Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
por: Li, Xiaoling, et al.
Publicado: (2022)

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
por: Pasternak, Björn, et al.
Publicado: (2020)

Sex differences in cardiovascular risk, lifestyle, and psychological factors in patients with type 2 diabetes: the Fukuoka Diabetes Registry
por: Ohkuma, Toshiaki, et al.
Publicado: (2023)

Gastrointestinal Bleeding in Acute Ischemic Stroke: Recent Trends from the Fukuoka Stroke Registry
por: Ogata, Toshiyasu, et al.
Publicado: (2014)

Anti-Cyclic Citrullinated Peptide Antibody-Positive Meningoencephalitis in the Preclinical Period of Rheumatoid Arthritis
por: Shibahara, Tomoya, et al.
Publicado: (2016)

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)
por: Kitazono, Takanari, et al.
Publicado: (2023)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Malnutrition-Inflammation Complex Syndrome and Bone Fractures and Cardiovascular Disease Events in Patients Undergoing Hemodialysis: The Q-Cohort Study
por: Yamada, Shunsuke, et al.
Publicado: (2022)

Slowly Progressive and Painless Thoracic Aortic Dissection Presenting with a Persistent Fever in an Elderly Patient: The Usefulness of Combined Measurement of Biochemical Parameters
por: Yamada, Shunsuke, et al.
Publicado: (2013)

The Transient Receptor Potential Vanilloid 4 Channel and Cardiovascular Disease Risk Factors
por: Goto, Kenichi, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
por: Suvarna, Viraj Ramesh
Publicado: (2021)

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials
por: Bose, Debdipta, et al.
Publicado: (2023)

Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy
por: Wakisaka, Masarori, et al.
Publicado: (2017)

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma
por: Kuang, Haoyu, et al.
Publicado: (2017)

Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2021)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care
por: Hinton, W., et al.
Publicado: (2020)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Afzal, Muhammad, et al.
Publicado: (2021)

Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation: Sub-analysis of the EXPAND Study
por: Uchiyama, Shinichiro, et al.
Publicado: (2018)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t067tndqtk4fs18mhvkh9sq9dc